Arcoma AB Share Price Nasdaq Stockholm
Equities
Advanced Medical Equipment & Technology
End-of-day quote
Other stock markets
|
||
- | - |
25/04 | Arcoma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
29/01 | Arcoma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 18Cr 1.72Cr 0 143.29Cr | Sales 2025 * | 20Cr 1.87Cr 0 155.82Cr | Capitalization | 19Cr 1.78Cr 0 148.67Cr |
---|---|---|---|---|---|
Net income 2024 * | 1.4Cr 13.15L - 11Cr | Net income 2025 * | 1.6Cr 15.02L - 13Cr | EV / Sales 2024 * | 1 x |
Net cash position 2024 * | 70L 7L 0 5.48Cr | Net cash position 2025 * | 1.9Cr 17.84L 0 15Cr | EV / Sales 2025 * | 0.86 x |
P/E ratio 2024 * |
14
x | P/E ratio 2025 * |
11.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.16% |
Managers | Title | Age | Since |
---|---|---|---|
Johan Dahlberg
DFI | Director of Finance/CFO | 40 | 01/22/01 |
Chief Tech/Sci/R&D Officer | 53 | 01/94/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 01/22/01 | |
Director/Board Member | 53 | 01/10/01 | |
Lars Kvarnhem
CHM | Chairman | 52 | 01/17/01 |
1st Jan change | Capi. | |
---|---|---|
-2.78% | 1.54TCr | |
-37.28% | 292.37Cr | |
-12.11% | 248.24Cr | |
-14.23% | 145.42Cr | |
-.--% | 112.5Cr | |
+66.72% | 61Cr | |
+90.77% | 50Cr | |
+18.98% | 25Cr | |
-2.35% | 22Cr |